Remove Drug Delivery Remove Drug Delivery Systems Remove FDA Approval Remove Life Science
article thumbnail

FDA Authorizes Pfizer COVID-19 Vaccine for Children 5 to 11 + Genentech’s Ocular Implant for Macular Degeneration – Xtalks Life Science Podcast Ep. 35

XTalks

The team also learned about the FDA approval of Genentech’s new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). Read the full articles here: FDA Authorizes Pfizer/BioNTech COVID-19 Vaccine for Kids 5 to 11.

article thumbnail

FDA Approves AbbVie’s Vuity as the First Eyedrop for Presbyopia

XTalks

Related: Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer. The FDA approval of Vuity exemplifies our continued pursuit of innovative new treatments that push the boundaries of what’s possible in eye care.”. Vuity is available by prescription.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five key drug discovery deals of summer 2023

Drug Discovery World

The life sciences sector has seen significant M&A activity over the last few weeks. The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.

Drugs 52
article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83